Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer

Although the prognosis of differentiated thyroid cancer (DTC) is relatively good, 30-40% of patients with distant metastases develop resistance to radioactive iodine therapy due to tumor dedifferentiation. For DTC patients harboring BRAF(V600E) mutation, Vemurafenib, a BRAF kinase inhibitor, has dra...

詳細記述

保存先:
書誌詳細
出版年:Theranostics
主要な著者: Wei, Wei-Jun, Sun, Zhen-Kui, Shen, Chen-Tian, Song, Hong-Jun, Zhang, Xin-Yun, Qiu, Zhong-Ling, Luo, Quan-Yong
フォーマット: Artigo
言語:Inglês
出版事項: Ivyspring International Publisher 2017
主題:
Research Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5381260/
https://ncbi.nlm.nih.gov/pubmed/28382170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.17322
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料